Clinical trials: Vehicle, completed
Meibomian Gland Dysfunction
Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
AZ202001 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD)
- Trial name
- NCT04391959
- Testing
- AZR-MD-001 Active, AZR-MD-001 Vehicle
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 31 people
- Sponsor
- Azura Ophthalmics
Presbyopia
A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.
The purpose of this study was to assess the effect of topical UNR844-Cl (lipoic acid choline ester chloride) ophthalmic solution on near visual function in presbyopic subjects.
- Trial name
- NCT03809611
- Testing
- UNR844-Cl
- Where
- 14 sites in United States
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)
The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.
- Trial name
- DUAL (NCT04451330)
- Testing
- Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 202 people
- Sponsor
- Galderma R&D
Postmenopausal Vulvovaginal Atrophy
Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
Study if WC3011 is effective and safe in the treatment of postmenopausal vaginal dryness due to vulvovaginal atrophy.
- Trial name
- VENUS (NCT01400776)
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 70 sites in United States
- Volunteers
- 722 people
- Sponsor
- Warner Chilcott
Vulvovaginal Atrophy
Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women
The primary objective of this study is to compare the efficacy of WC3011 with placebo vaginal gel in postmenopausal women for the relief of vaginal dryness caused by vaginal atrophy as measured by self-assessment, vaginal pH and…
- Trial name
- NCT01816139
- Testing
- Vehicle, WC3011 Estradiol Vaginal Cream
- Where
- 48 sites in United States
- Volunteers
- 576 people
- Sponsor
- Warner Chilcott
Vulvovaginal Atrophy
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
- Trial name
- NCT01845649
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 57 sites in United States
- Volunteers
- 550 people
- Sponsor
- Warner Chilcott
Stasis Dermatitis
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
This is a Phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of concept study that will include participants with stasis dermatitis without active skin ulceration, who will receive crisaborole ointment…
- Trial name
- NCT04091087
- Testing
- crisaborole ointment, vehicle ointment
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Pfizer
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03326856
- Testing
- botulinum toxin, Type A, Vehicle
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Eirion Therapeutics Inc.
Lateral Canthal Lines, Crow's Feet
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
- Trial name
- NCT03655691
- Testing
- Vehicle, botulinum toxin, Type A
- Where
- 6 sites in United States
- Volunteers
- 79 people
- Sponsor
- Eirion Therapeutics Inc.
Acne Vulgaris
Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris
The objective of this study is to assess safety and efficacy of various doses of BTX 1503 liquid formulation in subjects with moderate to severe acne vulgaris of the face.
- Trial name
- NCT03573518
- Testing
- BTX 1503, Vehicle
- Where
- 36 sites in United States, Australia
- Volunteers
- 368 people
- Sponsor
- Botanix Pharmaceuticals
Diabetic Foot Ulcer, Diabetes Mellitus
CSTC1 for Diabetic Foot Ulcers Phase II Study
The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with diabetic foot ulcers.
- Conditions
- Diabetic Foot Ulcer, Diabetes Mellitus, Wounds
- Trial name
- NCT01813305
- Testing
- CSTC1, CSTC1 Matched vehicle
- Where
- Taiwan
- Volunteers
- 124 people
- Sponsor
- Charsire Biotechnology Corp.
Facial Hyperpigmentation
Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation
Facial hyperpigmentation is a common skin issue that can cause embarrassment and affect the quality of life in majority of people.
- Trial name
- NCT03926845
- Testing
- Isobutylamido-thiazolyl-resorcinol Cream 0.2%, Vehicle
- Where
- Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute of Dermatology, Thailand
Actinic Keratoses
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and…
- Trial name
- NCT04085367
- Testing
- MAL 16.8% cream, MAL Vehicle Cream
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Galderma R&D
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Wound Heal, Scar
Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions
The pilot study is prospective, randomized, double-blinded, with intra-subject comparisons against a vehicle control. The primary objective of this pilot study is to investigate the safety and effectiveness of a new wound care…
- Conditions
- Wound Heal, Scar, Keloid, Surgical Wound
- Trial name
- NCT04169438
- Testing
- Vehicle Cream Base Emulsion Moisturizer + Petrolatum, FS2 Emulsion Moisturizer + Petrolatum
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The Center for Clinical and Cosmetic Research
Plaque Psoriasis
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045%…
- Trial name
- NCT05282771
- Testing
- Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
- Where
- United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin.
- Conditions
- Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
- Trial name
- NCT02960997
- Testing
- Sirolimus, 2%, Vehicle
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Dry Eye Disease
Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
The objective of this study is to evaluate the safety and effectiveness of OC-02 nasal spray compared to placebo on signs and symptoms of dry eye disease (DED).
- Trial name
- NCT03633461
- Testing
- OC-02 (simpinicline) nasal spray
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Oyster Point Pharma, Inc.
Dry Eye Disease
Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease
The primary objective of this study is to evaluate the safety and tolerability of iNexin™ The secondary objective is to compare the efficacy of iNexin™ to Vehicle for the treatment of the signs and symptoms associated with dry…
- Trial name
- NCT05031806
- Testing
- iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Xequel Bio, Inc.
Keratoconus, Corneal Ectasia
Safety and Preliminary Efficacy of IVMED-80 Eye Drops in Keratoconus Patients
We investigated the use of a copper sulfate eye drop (IVMED-80) for the treatment of keratoconus. Preliminary laboratory data shows that the addition of copper sulfate increase crosslinking of the structural proteins of the…
- Trial name
- NCT05241145
- Testing
- IVMED-80
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- iVeena Delivery Systems, Inc.